Invea Therapeutics

Invea Therapeutics, Inc. is a biotechnology company focused on developing oral small-molecule therapies for immune-mediated inflammatory diseases (IMIDs). Currently, the company has two candidate products: INVA8001, aimed at treating chronic inducible urticaria, and INVA8003, which is in the early preclinical development stage and has broader applications across various IMIDs. INVA8001 is planned to advance into Phase 2a clinical development in the EU. By utilizing the AlphaMeld platform, which integrates advanced technologies such as artificial intelligence and machine learning, the company aims to identify and develop safe and effective oral therapies that not only address inflammation but also improve the quality of life for patients with IMIDs.